Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Goldman Sachs analyst expects positive updates from Vertex's first Investor Day as a public company on March 19, reiterates ...

Credit to its robust bankability, supreme technological capability, and the worldly renowned 210mm n-type TOPCon modules ...

Vertex reported solid fourth-quarter numbers ... Learn More » However, the "other product revenue" category could start to become more of a factor. Both the Alyftrek CF treatment and Jornavx ...

China's Trina Solar has introduced two new series of products featuring an N-TOPCon configuration. It designed the Vertex N line commercial, industrial, and utility-scale applications, and the ...

Revenue $2.91 billion $2.78 billion $2.52 billion 15.7% Net Income (non-GAAP) $1.04 billion N/A $1.10 billion ... and expenses related to new product launches. Vertex's non-GAAP EPS decrease ...

Vertex Impress Vira is the latest product of Vertex released in November ... Taking connectivity into consideration, the phone has b, g, n, n 5GHz, Dual band, Wi-Fi Hotspot, Wi-Fi Direct with ...

BMO Capital's revised price target suggests a positive outlook for Vertex's financial performance, driven by its latest product offering in the acute pain treatment landscape. With revenue growth ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...